Dyne Therapeutics (DYN) to Release Quarterly Earnings on Thursday

Dyne Therapeutics (NASDAQ:DYN) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Dyne Therapeutics to post earnings of ($0.74) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $15.38 on Thursday. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $25.00. The stock’s 50-day moving average price is $18.09 and its 200-day moving average price is $16.76. The stock has a market capitalization of $2.20 billion, a PE ratio of -4.20 and a beta of 1.30.

Analysts Set New Price Targets

A number of research firms recently issued reports on DYN. Morgan Stanley lifted their price target on shares of Dyne Therapeutics from $46.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $40.00 price objective on shares of Dyne Therapeutics in a report on Monday, December 8th. Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. JPMorgan Chase & Co. decreased their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Finally, Evercore lowered their price objective on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, December 15th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.41.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DYN. XTX Topco Ltd lifted its stake in shares of Dyne Therapeutics by 93.9% in the 4th quarter. XTX Topco Ltd now owns 56,661 shares of the company’s stock valued at $1,108,000 after purchasing an additional 27,446 shares during the last quarter. Virtus Investment Advisers LLC raised its holdings in Dyne Therapeutics by 75.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,806 shares of the company’s stock valued at $270,000 after buying an additional 5,937 shares during the period. Wellington Management Group LLP raised its holdings in Dyne Therapeutics by 12.4% in the 4th quarter. Wellington Management Group LLP now owns 47,096 shares of the company’s stock valued at $921,000 after buying an additional 5,181 shares during the period. SummitTX Capital L.P. lifted its position in Dyne Therapeutics by 83.1% in the fourth quarter. SummitTX Capital L.P. now owns 243,276 shares of the company’s stock valued at $4,758,000 after buying an additional 110,376 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at about $2,887,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.